Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate

CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 18, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million

CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 13, 2018 09:05 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Pricing of $37.5 Million Public Offering

CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 12, 2018 16:01 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 06, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B

Upon closing, VBI received gross proceeds of $11 million, consisting of an upfront payment and an equity investment at $3.05 per share from Brii BiosciencesVBI is eligible to receive an additional...
November 09, 2018 07:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update

-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of...
October 24, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)

CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
October 16, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
October 02, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018

Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
September 27, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference

CAMBRIDGE, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right